恩替卡韦治疗慢性乙型肝炎临床疗效分析  

Analysis of Clinical Curative Effect of Entecavir in Treatment of Chronic Hepatitis B

作　　者：马东凯[1] 

机构地区：[1]吉林省前卫医院消化科,吉林长春130012

出　　处：《中外医疗》2017年第9期109-110,113,共3页China & Foreign Medical Treatment

摘　　要：目的探讨恩替卡韦对慢性乙型肝炎的治疗效果。方法方便选取2015年11月—2016年12月来该院治疗的124例慢性乙型肝炎患者为研究对象,随机分为两组,每组62例,观察组患者给予恩替卡韦片治疗,对照组患者给予拉米夫定治疗,比较两药物的治疗效果及不良反应等情况。结果两组患者在药物治疗后HBVDNA定量均有所下降(治疗前对照组和观察组患者平均HBVDNA定量的对数值分别为(7.35±2.08)和(7.56±1.87),但是观察组患者下降更明显,而且观察组患者在治疗12、24、48周后血清中HBVDNA定量、HBVDNA转阴率及肝功能ALT复常率情况均好于对照组,48周对照组和观察组的治疗结果分别为(3.31±1.06)和(2.76±1.19)、80.98%和94.35%、81.39%和95.27%,差异有统计学意义;观察组患者出现药物不良反应情况明显少于对照组,不良反应率分别为4.84%和19.35%,差异有统计学意义。结论恩替卡韦片治疗慢性乙型肝炎,不仅治疗效果好,而且不良反应少,提高患者生活质量,值得临床推广应用。Objective To discuss the clinical curative effect of Entecavir in treatment of Chronic Hepatitis B. Methods Convenient selection 124 cases of patients with chronic hepatitis B treated in our hospital from November 2015 to December 2016 were selected as the research objects and randomly divided into two groups with 62 cases in each, the observation group were treated with entecavir, while the control group were treated with lamivudine, and the drug treatment effect and adverse reactions were compared between the two groups. Results After treatment, the HBVDNA quantification of the two groups decreased（before treatment, the average HBVDNA quantification values were respectively（7.35 ±2.08） and（7.56±1.87）, but the decrease degree in the observation group was more obvious, and the serum HBVDNA quantification, HBVDNA negative conversion ratio and ALT normalization rate of liver function in 12, 24 weeks and 48 weeks after treatment in the observation group were better than those in the control group, and the differences in the treatment results between the control group and the observation group at 48 weeks were statistically significant [（3.31±1.06） vs（2.76±1.19）, 80.98% vs94.35%, 81.39% vs 95.27%], and the drug adverse reaction in the observation group was obviously fewer than that in the control group, and the adverse reaction rate was respectively 4.84% and 19.35%, and the difference was statistically significant. Conclusion The effect of entecavir in treatment of chronic hepatitis B is good with fewer adverse reactions, which can improve the quality of life of patients, and it is worth clinical promotion and application.

关 键 词：恩替卡韦片 慢性乙型肝炎 疗效分析 

分 类 号：R512.62[医药卫生—内科学]